The prognostic value of the proliferation marker Phosphohistone H3 (PPH3) in luminal, basal-like and triple negative phenotype invasive lymph node-negative breast cancer

Cellular Oncology

Volumn 31, Issue 4, 2009, Pages 261-271

  Skaland, Ivar ^a,b   Janssen, Emiel A M ^a   Gudlaugsson, Einar ^a,b   Hui Ru Guo, Lydia ^c   Baak, Jan P A ^a,b,d  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Basal like; Breast cancer; Phosphohistone H3; Prognosis; Proliferation

Indexed keywords

CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HISTONE H3; PHOSPHOHISTONE H3; PROGESTERONE RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HISTONES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 68249109135     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: 10.3233/CLO-2009-0464     Document Type: Article

References (35)

1. J.B.Arnes, K. Collett and L.A. Akselen, Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell, marker BMI-1, Histopathology 52 (2008), 370-380.
2. J.P. Baak, C.G. Colpaert, P.J. van Diest, E. Janssen, B. van Diermen, E. Albernaz, P.B. Vermeulen and E.A. Van Marck, Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers, Eur. J. Cancer 41 (2005), 2093-2101.
3. J.P. Baak, RJ. van Diest, F.J. Voorhorst, E. van der Wall, L.V. Beex, J.B. Vermorken and E.A. Janssen, Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years, J. Clin. Oncol. 23 (2005), 5993-6001.
4. J.P. Baak, P.J. van Diest, F.J. Voorhorst, E. van der Wall, L.V. Beex, J.B. Vermorken, E.A. Janssen, E. Gudlaugsson and other collaborators of the Multicenter Morphometric Mammary Carcinoma Project (MMMCP), The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent, Eur. J. Cancer 43 (2007), 527-535.
5. J.P. Baak, P.J. van Diest, E.A. Janssen, E. Gudlaugsson, F.J. Voorhorst, E. van der Wall, J.B. Vermorken and Collaborators of Multicenter Morphometric Mammary CarcinomaProject (MMMCP), Proliferation accurately identifies the highrisk patients among small, low-grade, lymph node-negative invasive breast cancers, Ann. Oncol. 19 (2008), 649-654.
6. C. Bossard, A. Jarry, C. Colombeix, K. Bach-Ngohou, A. Moreau, D. Loussouarn, J.F. Mosnier and C.L. Laboisse, Phosphohistone H3 labelling for histoprognostic grading of breast adenocarcinomas and computer-assisted determination of mitotic index, J. Clin. Pathol. 59 (2006), 706-710.
7. S. Calza, P. Hall, G. Auer, J. Bjöhle, S. Klaar, U. Kronenwett, E.T. Liu, L. Miller, A. Ploner, J. Smeds, J. Bergh and Y. Pawitan, Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients, Breast Cancer Res. 8 (2006), R34.
8. M.C. Cheang, D.Voduc, C. Bajdik, S. Leung, S. McKinney, S.K. Chia, CM. Perou and T.O. Nielsen, Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype, Clin. Cancer Res. 14 (2008), 1368-1376.
9. K. Collett, I.M. Stefansson, J. Eide, A. Braaten, H. Wang, G.E. Eide, S.Ø. Thoresen, W.D. Foulkes and L.A. Akslen, A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors, Cancer Epidemiol. Biomarkers Prev. 14(2005), 1108-1112.
10. J.S. de Jong, P.J. van Diest and J.P. Baak, Hot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancer, Histopathology 36(2000), 306-312.
11. C.W. Elston and I.O. Ellis, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology 19 (1991), 403-410.
12. R.K. Farmen, O. Nordga&̊rd, B. Gilje, F.V. Shammas, J.T. Kvaløy, S. Oltedal and R. Heikkilä, Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients, Breast Cancer Res. Treat. 108(2008), 251-258.
13. F. Jänicke, A. Prechtl, C. Thomssen, N. Harbeck, C. Meisner, M. Untch, C.G. Sweep, H.K. Selbmann, H. Graeff and M. Schmitt, Randomized adjuvant chemotherapy trial in highrisk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1, J. Natl. Cancer Inst. 93 (2001), 913-920.
14. E.A. Janssen, H. Søiland, I. Skaland, E. Gudlaugson, K.H. Kjellevold, A. Nysted, J.A. Søreide and J.P. Baak, Comparing the prognostic value of PTEN and Akt expression with the Mitotic Activity Index in adjuvant chemotherapy-treated nodenegative breast cancer patients aged < 55 years, Cell Oncol. 29 (2007), 25-35.
15. E.A. Janssen, P.J. van Diest, H. Søiland, E. Gudlaugson, A. Nysted, F.J. Voorhorst, J.B. Vermorken, J.A. Søreide and J.P. Baak, Success predictors of adjuvant chemotherapy in nodenegative breast cancer patients under 55 years, Cell Oncol. 28 (2006), 295-303.
16. B. Kreike, M. van Kouwenhove, H. Horlings, B. Weigelt, H. Peterse, H. Bartelink and M.J van de Vijver, Gene expression profiling and histopathological characterization oftriplenegative/basal-like breast carcinomas, Breast Cancer Res. 9 (2007), R65.
17. G. La Rocca, R. Anzalone, S. Corrao, F. Magno, F. Rappa, S. Marasà, A.M. Czarnecka, L. Marasà, C. Sergi, G. Zummo and F. Cappello, CDIa down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome, Histopathology 52 (2008), 203-212.
18. M.T. Nevalainen, J. Xie, J. Torhorst, L. Bubendorf, P. Haas, J. Kononen, G. Sauter and H. Rui, Signal transducer and activator of transcription-5 activation and breast cancer prognosis, J. Clin. Oncol. 22 (2004), 2053-2060.
19. T.O. Nielsen, F.D. Hsu, K. Jensen, M. Cheang, G. Karaca, Z. Hu, T. Hernandez-Boussard, C. Livasy, D. Cowan, L. Dressier, L.A. Akslen, J. Ragaz, A.M. Gown, C.B. Gilks, M. van de Rijn and CM. Perou, Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma, Clin. Cancer Res. 10 (2004), 5367-5374.
20. CM. Perou, T. Sørlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T. Ross, H. Johnsen, L.A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S.X. Zhu, P.E. Lønning, A.L. Børresen-Dale, P.O. Brown and D. Botstein, Molecular portraits of human breast tumours, Nature 406 (2000), 747-752.
21. E.A. Rakha, M.E. El-Sayed, J. Reis-Filho and I.O. Ellis, Pathobiological aspects of basal-like breast cancer, Breast Cancer Res. Treat. (2008) Mar. 9. [Epub ahead of print.]
22. E.A. Rakha, M.E. El-Sayed, A.R. Green, E.C. Paish, A.H. Lee and I.O. Ellis, Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression, Histopathology 50 (2007), 434-438.
23. E.A. Rakha, M.E. El-Sayed, A.R. Green, A.H. Lee, J.F. Robertson and I.O. Ellis, Prognostic markers in triple-negative breast cancer, Cancer 109 (2007), 25-32.
24. J.S. Reis-Filho and A.N. Tutt, Triple negative tumours: a critical review, Histopathology 52 (2008), 108-118.
25. R. Rouzier, C.M. Perou, W.F. Symmans, N. Ibrahim, M. Cristofanilli, K. Anderson, K.R. Hess, J.Stec, M. Ayers, P. Wagner, P. Morandi, C. Fan, I. Rabiul, J.S. Ross, G.N. Hortobagyi and L. Pusztai, Breast cancer molecular subtypes respond differently to preoperative chemotherapy, Clin. Cancer Res. 11 (2005), 5678-5685.
26. I. Skaland, E.A. Janssen, E. Gudlaugsson, J. Klos, K.H. Kjellevold, H. Søiland and J.P. Baak, Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age, Mod. Pathol. 20 (2007), 1307-1315.
27. I. Skaland, E.A. Janssen, E. Gudlaugsson, J. Klos, K.H. Kjellevold, H. Søiland and J.P. Baak, Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age, Breast Cancer Res. Treat. (2008) Mar. 29. [Epub ahead of print.]
28. I. Skaland, P.J. van Diest, E.A. Janssen, E. Gudlaugsson and J.P. Baak, Prognostic differences of World Health Organization - assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years, Hum. Pathol. 39 (2008), 584-590.
29. T. Sortie, R. Tibshirani, J. Parker, T. Hastie, J.S. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich, S. Geisler, J. Demeter, CM. Perou, P.E. Lønning, P.O. Brown, A.L. Børresen-Daleand D. Botstein, Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc. Natl. Acad. Sci. USA 100 (2003), 8418-8423.
30. T. Sørlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, T. Thorsen, H. Quist, J.C. Matese, P.O. Brown, D. Botstein, P. Eystein Lønning and A.L. Børresen-Dale, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc. Natl. Acad Sci. USA 98 (2001), 10869-10874.
31. C. Sotiriou and M.J. Piccart, Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care, Nat. Rev. Cancer 7 (2007), 545-553.
32. D.S. Tan, C. Marchió, R.L. Jones, K. Savage, I.E. Smith, M. Dowsett and J.S. Reis-Filho, Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients, Breast Cancer Res. Treat.(2007) Oct. 6 [Epub].
33. RA. Tavassoli and P. Devilee, Pathology and genetics: Tumours of the breast and female genital organs, WHO classification of tumours series, IARC Press, Lyon, 2003, pp. 9-112.
34. P.J. van Diest, E. van der Wall and J.P. Baak, Prognostic value of proliferation in invasive breast cancer: a review, J. Clin. Pathol. 57 (2004), 675-681.
35. V. Vuaroqueaux, P. Urban, M. Labuhn, M. Delorenzi, P. Wirapati, C.C. Benz, R. Flury, H. Dieterich, F. Spyratos, U. Eppenberger and S. Eppenberger-Castori, Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome, Breast Cancer Res. 9 (2007), R33.